steering committees and working groups to ensure appropriate project implementation, oversight, and management for all projects under the PPP.

- Development of a scientific review panel to evaluate the progress of projects funded under the PPP and development of feasibility plans for additional projects aligned with PASI.
- Coordination with FDA and other partners; the development and publication of scientific articles in support of educational and outreach activities (with data, know-how, and other outcomes from the aforementioned projects supported under the PPP) and to benefit patients and other stakeholders.
- Development of a strategy to identify and establish relationships with key experts in the fields of anesthesia and sedation, including stakeholders from industry, professional organizations, academia, and awardees of the projects under the “research and analysis” section for leveraging and collaborative efforts under PASI.
- Coordination of annual scientific workshops with collaboration by FDA and the aforementioned experts in the fields of anesthesia and sedation, including stakeholders from industry, professional organizations, academia, and Government Agencies.

2. Research projects (which may include, but are not limited to):
- Clinical trials including prospective, randomized, and blinded investigations assessing the immediate and delayed neurodevelopmental effects of regional/caudal anesthesia versus general anesthesia in neonates/infants;
- Observational trials including the comparison of two groups of children, one group exposed to general anesthesia and the other, unexposed. Assessments should utilize neuropsychological tests of attention, memory, motor function, and behavior; and
- Epidemiologic investigations surveying large existing population databases for cognitive developmental effects where exposure to general anesthesia before the age of 3 can be compared to the overall population.

C. Eligibility Information

Higher education institutions:
- Public/state-controlled institutions of higher education
- Private institutions of higher education

The following types of higher education institutions are always encouraged to apply for National Institutes of Health support as public or private institutions of higher education:
- Hispanic serving institutions
- Historically Black colleges and universities
- Tribally controlled colleges and universities
- Alaska Native and Native Hawaiian serving institutions
- Nonprofits other than institutions of higher education
- Nonprofits with 501(c)(3) Internal Revenue Service (IRS) status (other than institutions of higher education)
- Nonprofits without 501(c)(3) IRS status (other than institutions of higher education)
- For-profit organizations:
  - Small businesses
  - For-profit organizations (other than small businesses)
- Other:
  - Regional organizations
  - Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply. Foreign (non-U.S.) components of U.S. organizations are not allowed.

II. Award Information/Funds Available

A. Award Amount

FDA intends to fund one or more awards, corresponding to a total of $1 million, for fiscal year 2011, to carry out the project management and research project objectives described in Part I of this document. Future year amounts will depend on annual appropriations. No more than four awards are anticipated under this FOA. The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications.

B. Length of Support

The anticipated length of the individual awards is 5 years.

III. Electronic Application, Registration, and Submission

Only electronic applications will be accepted. To submit an electronic application in response to this FOA, applicants should first review the full announcement located at http://grants.nih.gov/grants/guide/ (select the “Request for Applications” link), http://www.grants.gov/ (see “For Applicants” section) and http://wda.fda.gov/AboutFDA/PartnershipsCollaborations/PublicPrivatePartnershipProgram/ucm166082.htm. (FDA has verified the Web site addresses throughout this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.) For all electronically submitted applications, the following steps are required:

- Step 1: Obtain a Dun and Bradstreet (DUNS) Number
- Step 2: Register With Central Contractor Registration
- Step 3: Obtain Username and Password
- Step 4: Authorized Organization Representative (AOR) Authorization
- Step 5: Track AOR Status
- Step 6: Register With Electronic Research Administration (eRA) Commons Step 1 through 5, in detail, can be found at http://www07.grants.gov/applicants/organization_registration.jsp. Step 6, in detail, can be found at https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp. After you have followed these steps, submit electronic applications to: http://www.grants.gov.

Dated: March 21, 2011.

Leslie Kux,
Acting Assistant Commissioner for Policy.

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel; LOAN REPAYMENT.

Date: April 7, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Carol Lambert, Ph.D., Scientific Review Officer, Office of Review, NCRR, National Institutes of Health, 6701 Democracy Blvd., One Democracy Plaza, Room 1076, MSC 4874, Bethesda, MD 20892–4874, 301–435–0814, lambert@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Host Response to Allergy and Infectious Diseases Special Emphasis Panel; Mechanisms of Neurodegeneration.

Date: June 9–10, 2011.

Time: 8:30 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20852.

Contact Person: Beata Buzas, PhD, Scientific Review Officer, National Institute on Alcohol Abuse and Alcoholism Initial Review Group; Neuroscience Review Subcommittee.

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency


Utah; Amendment No. 1 to Notice of a Major Disaster Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

SUMMARY: This notice amends the notice of a major disaster declaration for the State of Utah (FEMA–1955–DR), dated February 11, 2011, and related determinations.

DATES: Effective Date: March 11, 2011.

FOR FURTHER INFORMATION CONTACT: Peggy Miller, Office of Response and Recovery, Federal Emergency